Atlas Trials

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical trial NCT01602315 · TERMINATED

Trial details

NCT number
NCT01602315
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Start date
2012-11-12
Primary completion
2016-09-16
Enrollment
179

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.